Results 101 to 110 of about 37,430 (216)

Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis

International Journal of Dermatology, EarlyView.
Chronic prurigo, including prurigo nodularis, is a chronic, often treatment‐refractory condition characterized by persistent pruritus and chronic scratch lesions. Advances in the understanding of its underlying pathophysiology have enabled the development of novel targeted therapies; however, management remains challenging due to the expanding range of
Simon M. Mueller, Helmut Beltraminelli, Wolf‐Henning Boehncke, Maximilian Böhm, Antonio Cozzio, Peter Häusermann, Ahmad Jalili, Antonios G. A. Kolios, Claudia Lang, Eva Loos, Christoph Schlapbach, Curdin Conrad   +11 more
wiley   +1 more source

Comparison of thalidomide and lenalidomide as therapy for myelofibrosis

, 2011
With the use of the International Working Group for Myelofibrosis Treatment and Research consensus criteria, we re-assessed the efficacy of thalidomide and lenalidomide in 125 patients with myelofibrosis treated in 3 consecutive phase 2 trials: 44 ...
Sherry Pierce, Hagop Kantarjian, Elias Jabbour, Jorge Cortes, Deborah Thomas, Lingsha Zhou, Srdan Verstovsek   +6 more
core   +1 more source

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients [PDF]

, 2018
We recently showed that the outcome of multiple myeloma (MM) patients treated in the REPEAT study (evaluation of lenalidomide combined with low-dose cyclophosphamide and prednisone (REP) in lenalidomide-refractory MM) was markedly better than what has ...
Bjorklund, CC, Zweegman, S, van Kessel, B, Bloem, Andries C, Broijl, Annemiek, Emmelot, M, Zweegman, Sonja, Franssen, L E, Koene, HR, Klein, Saskia K, Nijhof, Inger S., Faber, LM, Levin, M-D, Faber, Laura M., Lokhorst, Henk M., van der Spek, E, Nijhof, I S, Bloem, AC, Lokhorst, Henk M, Emmelot, Maarten, Franssen, Laurens E., Mutis, T, Qian, Xiaozhong, Van De Donk, Niels W.C.J., Bjorklund, Chad C, Koene, Harry R, Thakurta, Anjan, Bos, Gerard M.J., Nijhof, Inger S, Levin, Mark David, Raymakers, Reinier, Beeker, Aart, Klein, SK, Raymakers, R, Bos, GMJ, Qian, X, van de Donk, Niels W C J, van Velzen, Jeroen, Sonneveld, Pieter, Bjorklund, Chad C., Klein, Saskia K., van Velzen, J, Bos, Gerard M J, Bloem, Andries C., Broijl, A., Doorn, Ruud, Koene, Harry R., Franssen, Laurens E, Chiu, H, Levin, Mark-David, van der Spek, Ellen, van Doorn, R, Thakurta, A, Mutis, Tuna, Chiu, Hsiling, van Kessel, Berris, Faber, Laura M, Beeker, A, Lokhorst, HM, v.d. Donk, NWCJ   +59 more
core   +1 more source

Treatment of plasma cell dyscrasias with lenalidomide

, 2008
Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, with pleiotropic activity including antiangiogenic and antineoplastic properties.
Rajkumar, S.V., Rajkumar, SV, Dimopoulos, MA, Kastritis, E, Dimopoulos, M.A., Kastritis, E.   +5 more
core   +1 more source

Real‐world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara‐VTd) induction and lenalidomide maintenance in transplant‐eligible multiple myeloma

British Journal of Haematology, EarlyView.
Edvan Q. Crusoé, Glaciano Ribeiro, João Tadeu D. Souto Filho, Jayr Schmidt Filho, Natalia Schutz, Milton A. F. Aranha, Abel Costa, Abrahao Hallack, Fernando V. Pericole, Juliana S. Lima, Breno Gusmão, Eduardo Flávio O. Ribeiro, Jorge P. Vaz, Rosane Bittencourt, Rafael Cunha, Danielle Ovigli, Luiza Berg, Ederson R. Mattos, Angelo Maiolino, Vania Hungria, on behalf of GBRAM   +20 more
wiley   +1 more source

The Legitimacy Trap: How Regulators' Credibility‐Building Constrains Responsiveness Under Politicization

Regulation &Governance, EarlyView.
ABSTRACT This article develops an analytical framework for understanding regulators' struggles for legitimacy, highlighting tensions between two key sources: credibility and responsiveness. A regulator must earn credibility with actors around the regulatory arena, but organizational tools for credibility‐building, including codified rules and mobilized
Takuya Onoda
wiley   +1 more source

Forest plot of the relative risks for AML progression in case group (lenalidomide-treated) and control group (lenalidomide-untreated).

, 2016
Forest plot of the relative risks for AML progression in case group (lenalidomide-treated) and control group (lenalidomide-untreated).
Xin-yue Lian (3337185), Lei Yang (102719), Pin-fang He (3337182), Dong-ming Yao (135624), Xiang-mei Wen (679529), Jiang Lin (135625), Zi-jun Xu (2200591), Jun Qian (108736), Zhao-qun Deng (135633), Zhi-hui Zhang (1771039)   +9 more
core   +1 more source

Cytomegalovirus Retinitis Associated with Lenalidomide Use for Multiple Myeloma in an Immunocompetent Patient

Case Reports in Ophthalmological Medicine, 2019
Purpose. The aim of this report is to present a case of cytomegalovirus (CMV) retinitis in an immunocompetent patient using lenalidomide. Methods.
Matthew K. Adams, Christina Y. Weng
doaj   +1 more source

Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care

European Journal of Haematology, Volume 117, Issue 5, Page 1181-1197, November 2026.
ABSTRACT Multiple myeloma (MM) is predominantly a disease of older adults, yet the randomized clinical trials (RCTs) that define standards of care are conducted largely in younger, fitter, and less comorbid populations. This creates a systematic mismatch between the populations generating evidence and those receiving treatment in routine practice ...
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Santino Caserta, Eugenio Lucia, Graziella D'Arrigo, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Giovanni Tripepi, Fortunato Morabito, Massimo Gentile   +13 more
wiley   +1 more source

Continuous lenalidomide treatment for newly diagnosed multiple myeloma

, 2012
Lenalidomide has tumoricidal and immunomodulatory activity against multiple myeloma. This double-blind, multicenter, randomized study compared melphalan-prednisone-lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan ...
Yu, Zhinuan, Weisel, Katja, Cavo, Michele, Plesner, Torben, Mei, Jay, Spicka, Ivan, Ben Yehuda, Dina, Delforge, Michel, Catalano, John, Radke, Joergen, Iosava, Genadi, Wiktor-Jędrzejczak, Wiesław, Bladé, Joan, Dimopoulos, Meletios A, Kloczko, Janusz, Jacques, Christian, Palumbo, Antonio, Herbein, Lindsay, Langer, Christian, Beksac, Meral, Kropff, Martin, Cascavilla, Nicola, Gisslinger, Heinz, Zodelava, Mamia, Corso, Alessandro, Petrucci, Maria Teresa, Hajek, Roman   +26 more
core   +1 more source